The rise of AI is fundamentally reshaping the landscape of clinical research, challenging the traditional role of the “guru” or key opinion leader. In an age where vast amounts of public data are accessible to everyone, is the expert opinion still as valuable as it once was? The Democratization of Evidence For decades, the opinionsContinue reading “The Demise of the Clinical Research Guru in the AI Era”
Category Archives: Uncategorized
[Thought] Knowledge Work in the Age of AI
The rise of AI has led to a common prediction: the value of knowledge work is plummeting. With powerful tools that can generate text, summarize information, and write code in seconds, it seems that the days of high-value human expertise are numbered. After all, if an AI can do it, why would anyone pay aContinue reading “[Thought] Knowledge Work in the Age of AI”
[JUN 10,2025] Today’s trial: CONFIDENCE
P: Adults (≥18 years of age) with CKD and type 2 diabetes (T2D), estimated glomerular filtration rate (eGFR) of 30–90 mL/min/1.73 m2 and UACR of ≥100 to <5000 mg/g. I: EMPA+FINE combo C: Empagliflozin vs Finerenone O: At day 180, the reduction in the UACR with combination therapy was 29% greater than that with finerenone alone (least-squares mean ratioContinue reading “[JUN 10,2025] Today’s trial: CONFIDENCE”
[Thought] The Rising Cost of Original Training Data: Will Humans Become AI’s Data Providers?
As artificial intelligence (AI) systems evolve, they are becoming increasingly reliant on high-quality, original data to sustain their growth. However, the scarcity and rising cost of obtaining such data are posing significant challenges. A provocative concern is emerging in this context: could humans eventually become mere providers of data, akin to “livestock” for AI systems?Continue reading “[Thought] The Rising Cost of Original Training Data: Will Humans Become AI’s Data Providers?”
The concept of a Human Digital Twin
The publication titled “A Unified View of a Human Digital Twin” provides a structured and comprehensive exploration of the concept of a Human Digital Twin (HDT). Here is a summary of the key points related to the concept, based on the publication: Definition of Human Digital Twin A Human Digital Twin (HDT) is a virtualContinue reading “The concept of a Human Digital Twin”
[Paper] Management of heart failure in patients with kidney disease—updates from the 2021 ESC guidelines – Heart Failure Recommendations
Management of heart failure in patients with kidney disease—updates from the 2021 ESC guidelinesby Nicola C Edwards, et al.Nephrology Dialysis Transplantation, Volume 38, Issue 8, August 2023, Pages 1798–1806, https://doi.org/10.1093/ndt/gfad011 While clinical trials over almost 40 years have enabled the guidelines to recommend multiple drugs with clear evidence of prognostic benefit in HFrEF, data for HFmrEF andContinue reading “[Paper] Management of heart failure in patients with kidney disease—updates from the 2021 ESC guidelines – Heart Failure Recommendations”
[Paper] Management of heart failure in patients with kidney disease—updates from the 2021 ESC guidelines – Heart Failure Patients with Concomitant CKD
Management of heart failure in patients with kidney disease—updates from the 2021 ESC guidelinesby Nicola C Edwards, et al.Nephrology Dialysis Transplantation, Volume 38, Issue 8, August 2023, Pages 1798–1806, https://doi.org/10.1093/ndt/gfad011 The 2021 guidelines address the co-existence of HF and CKD in a short section titled ‘Non-cardiovascular co-morbidities’. This section remains brief as in 2016 and exemplifies theContinue reading “[Paper] Management of heart failure in patients with kidney disease—updates from the 2021 ESC guidelines – Heart Failure Patients with Concomitant CKD”
[Paper] Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in pre-diabetic mice
Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in pre-diabetic mice (https://doi.org/10.1152/ajpcell.00446.2023)by Blythe D. Shepard, et al. 04 MAR 2024 Sodium-glucose cotransporter, type 2 inhibitors (SGLT2i), particularly empagliflozin, are identified as promising agents for the treatment of type 2 diabetes (T2D) with additional benefits for renal protection beyond glucose reduction.Continue reading “[Paper] Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in pre-diabetic mice”
[Paper] New Developments in the Treatment and Management of Heart Failure: Managed Care Considerations on the Evolving Paradigm in HFrEF and HFpEF
New Developments in the Treatment and Management of Heart Failure: Managed Care Considerations on the Evolving Paradigm in HFrEF and HFpEF (JMCM_26.2_Apr2023_web.pdf (jmcmpub.org))by Alanna A. Morris, MD, MSc SummaryThe management of heart failure has undergone significant changes over the past few years. A four-pillar medication strategy is now recommended and this strategy includes two newerContinue reading “[Paper] New Developments in the Treatment and Management of Heart Failure: Managed Care Considerations on the Evolving Paradigm in HFrEF and HFpEF”
[Press] CES 2024 Sector Trends: Digital Health
CES 2024 Sector Trends: Digital Health (https://www.ces.tech/articles/2023/october/ces-2024-sector-trends-digital-health.aspx)CTA Staff| October 12, 2023 OVERVIEWWhat’s the outlook for digital health in America? CTA’s research-based diagnosis is systems, products and services for more personal, portable and precise care. As digital health exhibits and programming continue to take shape for CES 2024, top trends point to the sector’s offerings becomingContinue reading “[Press] CES 2024 Sector Trends: Digital Health”
Uthando Nethemba 